secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2026-03-23T23:59:59+00:00
Accession:  0001534120-26-000010
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics reports 2025 net loss of $78.3M; Phase 2 HS topline data due Q2 2026
--------------------------------------------------------------------------------

- Net loss $78.3M ($5.84 per share) vs $35.1M in 2024; operating expenses rose to $73M.
- Cash, equivalents and short-term investments $98.3M as of Dec 31, 2025; expected runway into 2028.
- R&D expenses $50.1M, up $25.6M YoY driven by Phase 2 LOTUS trial costs for abdakibart (AVTX-009).
- Topline data from Phase 2 abdakibart trial for hidradenitis suppurativa expected in Q2 2026.
- G&A expenses $22.9M, up $5.7M primarily from stock-based compensation and headcount additions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000010/0001534120-26-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000010/avtx-20260323.htm
  HTML page:      https://secwatch.observer/filing/0001534120-26-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer